Introduction
============

Hypertension is one of the crucial risk factors for progression of cardiovascular and cerebrovascular disease and mortality. Appropriate blood pressure (BP) management improves the prognosis in patients with hypertension.[@b1-tcrm-11-083] Despite the increased prevalence of hypertension and its associated complications, in addition to increased awareness of the condition, BP control has been inadequate.[@b2-tcrm-11-083] The 2009--2012 National Health and Nutrition Examination Survey showed that only 46%--51% of hypertensive patients have their BP under sufficient control, defined as a level below 140/90 mmHg.[@b3-tcrm-11-083]--[@b6-tcrm-11-083] Reasons for this high prevalence of uncontrolled BP could include insufficient doses of antihypertensive agents and/or poor adherence to the multidrug regimen. Consequently, treatment with a tablet that combines antihypertensive agents might improve patients' adherence with oral medication, thereby helping them to achieve target BP and reduce cardiovascular events.[@b7-tcrm-11-083],[@b8-tcrm-11-083]

The Japanese Society of Hypertension guidelines recommend combination therapy using a calcium channel blocker (CCB) and an angiotensin-converting enzyme inhibitor/angiotensin II receptor antagonist (ARB) for patients with resistant hypertension because these two drugs synergistically lower BP.[@b9-tcrm-11-083]

Recently, a combination tablet containing amlodipine 10 mg and irbesartan 100 mg (Aimix HD^®^; Dainippon Sumitomo Pharma Co Ltd, Osaka, Japan) that has a 24-hour antihypertensive effect has become available in Japan. However, the effects of the combination tablet with regard to lowering BP and other cardiovascular risk factors have not been studied. The aim of this study was to clarify the effects of the combination tablet on BP-lowering and reduction of other cardiovascular risk factors.

Materials and methods
=====================

We retrospectively evaluated data from 68 Japanese patients with essential hypertension whose treatment was changed from a combination of an independent ARB and a low-dose or regular-dose CCB or from a combination of an ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg. Previous treatment regimens did not include irbesartan as the ARB. The change in treatment was made because the patient's office and/or home systolic and/or diastolic BP did not reach the management target recommended by the Japanese Society of Hypertension guidelines.[@b9-tcrm-11-083] According to the drug information for hypertensive Japanese patients, a regular-dose ARB regimen is defined as valsartan 80 mg, telmisartan 40 mg, candesartan 8 mg, olmesartan 20 mg, or losartan 50 mg. A regular-dose CCB regimen is defined as amlodipine 5 mg, diltiazem 100 mg, cilnidipine 10 mg, nifedipine 40 mg, or benidipine 4 mg. A high dose is defined as a dose more than the regular dose, and a low dose is defined as a dose lower than the regular dose.

The patients were recruited from the Department of Cardiology at Tokushima University Hospital, Department of Internal Medicine at Shikoku Central Hospital, and Kanematsu Hospital between April 2013 and January 2014. Patients receiving other antihypertensive drugs, including diuretics, α-blockers, β-blockers, mineralocorticoid receptor antagonists, or direct renin inhibitors, were excluded. Patients with secondary hypertension, symptomatic active malignant disease, renal failure (serum creatinine level \>3.0 mg/dL), or liver dysfunction (aspartate aminotransferase \>100 IU/L, alanine aminotransferase \>100 IU/L) were also excluded.

Office BP was evaluated following the guidelines of the Japanese Society of Hypertension[@b9-tcrm-11-083] before and 3 months after the patients started receiving the combination tablet. Each patient recorded their home BP measurements in a notebook specifically describing BP management according to the guidelines.[@b9-tcrm-11-083] Measurements of biochemical parameters, including uric acid, low-density lipoprotein cholesterol (LDL-C), triglycerides, high-density lipoprotein cholesterol (HDL-C), plasma glucose, glycated hemoglobin (HbA~1c~), serum potassium and creatinine levels, and urinary albumin excretion rate were performed. The study protocol was approved by the ethics committees at Tokushima University Hospital and Shikoku Central Hospital.

Statistical analysis
--------------------

Differences in BP values and other biomarkers before and 3 months after starting the combination tablet were evaluated by the Wilcoxon signed-rank test. Multiple regression analysis was used to assess the correlation between BP and other indices. The analyses were performed using Microsoft Windows and JMP version 10 software. Statistical significance was considered at *P*\<0.05.

Results
=======

Patient clinical characteristics
--------------------------------

The characteristics of the patients enrolled in this study are shown in [Table 1](#t1-tcrm-11-083){ref-type="table"}. The previous antihypertensive drug regimen was a low, regular, or high dose of an ARB (except irbesartan) and a low or regular dose of a CCB ([Table 2](#t2-tcrm-11-083){ref-type="table"}). In the previous treatment regimen, 35 patients received an ARB/CCB combination tablet and 33 patients received independent ARB and CCB tablets (see [Supplementary Table 1](#SD1-tcrm-11-083){ref-type="supplementary-material"}).

Combination tablet containing amlodipine 10 mg and irbesartan 100 mg decreased BP
---------------------------------------------------------------------------------

The combination tablet significantly decreased systolic and diastolic BP, but did not affect heart rate ([Table 3](#t3-tcrm-11-083){ref-type="table"}). Three months of treatment with the combination tablet increased the rate of achievement of target BP from 0% to 70.5%.

Combination tablet containing amlodipine 10 mg and irbesartan 100 mg decreased serum uric acid levels
-----------------------------------------------------------------------------------------------------

The combination tablet significantly decreased serum uric acid levels ([Table 3](#t3-tcrm-11-083){ref-type="table"}). Multiple regression analysis showed that the decrease in serum uric acid was independent of decreases in systolic and diastolic BP in age-adjusted, sex-adjusted, and serum creatinine-adjusted models (data not shown).

Effect of amlodipine 10 mg and irbesartan 100 mg combination tablet on lipid profiles, plasma glucose levels, and renal function
--------------------------------------------------------------------------------------------------------------------------------

The combination tablet significantly reduced LDL-C and increased HDL-C levels but had no effect on triglyceride levels ([Table 3](#t3-tcrm-11-083){ref-type="table"}). Conversely, treatment with the combination tablet did not affect plasma glucose, HbA~1c~, serum potassium and creatinine levels, or urinary albumin excretion rate ([Table 3](#t3-tcrm-11-083){ref-type="table"}).

Multiple regression analysis showed that the decrease in LDL-C levels and increase in HDL-C levels were independent of the systolic and diastolic BP reduction, age, sex, body mass index, and administration of statins and/or ezetimibe (data not shown). In addition, multiple regression analysis showed that the changes in triglycerides, plasma glucose, HbA~1c~, serum creatinine, and urinary albumin excretion rate were independent of the changes in systolic and diastolic BP, age, sex, and body mass index (data not shown).

Adverse effects
---------------

Seven patients stopped taking the combination tablet. Three female patients felt slight faintness and another three female patients developed edema within 1 month of starting the combination tablet. One patient was diagnosed with gastric cancer 13 weeks after starting the combination medication.

Discussion
==========

The present study showed that treatment with a combination tablet containing amlodipine 10 mg and irbesartan 100 mg was effective in decreasing BP after switching from an ARB (without irbesartan) and from a low-dose or regular-dose CCB regimen. In addition, the combination tablet improved the lipid profile and decreased uric acid levels in a manner that was independent of BP reduction.

It has been emphasized that BP should be controlled to prevent cardiovascular and cerebrovascular events, with sufficient dose of antihypertensive drugs.[@b10-tcrm-11-083] Because of the low rate of goal achievement, strong and well tolerated BP-lowering drugs are needed. Increased doses of antihypertensive monotherapy often fail to control BP in patients with resistant hypertension; therefore, combination therapy with other types of drugs should be considered. Combination of an ARB and CCB lowers BP and reduces mortality to a greater extent than a high-dose ARB in patients with cardiovascular disease.[@b11-tcrm-11-083] Addition of a CCB is more effective at lowering BP than simply doubling the dose of an existing ARB;[@b11-tcrm-11-083] therefore, combination ARB/CCB therapy could be the first choice for treatment-resistant hypertension.[@b9-tcrm-11-083]

Because treatment with a CCB lowers BP in a dose-dependent manner,[@b12-tcrm-11-083] a combination tablet containing a high dose of amlodipine (10 mg) may result in further BP reduction compared with low or regular dose of CCB in the baseline treatment.

Adherence to antihypertensive treatment is a critical factor for BP management; 75% of compliant patients were shown to achieve their target BP of \<140/90 mmHg compared with only 10% of noncompliant patients.[@b13-tcrm-11-083] It has been shown that adherence to antihypertensive treatment is related to favorable/unfavorable BP control and the development/prognosis of cardiovascular disease. In addition, adherence improves when the number of tablets to be consumed are fewer and the dosing frequency is reduced.[@b9-tcrm-11-083] Combination therapy with a single pill might therefore be recommended to improve adherence, leading to prevention of cardiovascular disease.[@b9-tcrm-11-083] In this study, a reduced number of tablets might have contributed to decreased BP by improving adherence to the prescribed drugs.

In the present study, we observed a reduction in serum uric acid levels after treatment with the combination tablet. Because serum uric acid is a causative mediator of increased BP and impaired vascular compliance, and because serum uric acid levels are predictors of cardiovascular mortality, it might be important to control serum uric acid to prevent cardiovascular disease.[@b14-tcrm-11-083]--[@b16-tcrm-11-083] In hypertensive patients, increased angiotensin II secretion activates URAT1, leading to an increase in reabsorption of uric acid.[@b17-tcrm-11-083],[@b18-tcrm-11-083] Irbesartan inactivates both URAT1 and URATv1, which are reabsorptive transporters, suggesting that irbesartan has the ability to decrease serum uric acid levels.[@b19-tcrm-11-083] Uric acid-lowering therapy therefore could result in a significant reduction in systemic vascular resistance.

In the present study, we observed a decrease in LDL-C levels and an increase in HDL-C levels after the combination therapy was started. Although irbesartan is known to improve metabolic parameters, including LDL-C and HDL-C levels,[@b20-tcrm-11-083],[@b21-tcrm-11-083] its mechanism of action is unknown. Further research is required to clarify this issue.

Six patients experienced slight faintness or edema and stopped consuming the combination tablet. These adverse effects may be attributed to excessive BP-lowering effects and vasodilation due to the increased dose of amlodipine.

This study had several limitations. First, there was considerable heterogeneity of antihypertensive therapy before administration of the combination tablet. Second, this is a single-arm, relatively short-term, observational study with a small sample size. Third, we could not determine whether the reduction in BP was due to the effect of the combination treatment, the effect of irbesartan, or the effect of high-dose amlodipine.

Conclusion
==========

Treatment with a combination tablet containing amlodipine 10 mg and irbesartan 100 mg exerted further BP-lowering effects when compared with an ARB with a low-dose or regular-dose CCB. The combination tablet also had favorable effects on serum uric acid, LDL-C, and HDL-C levels in patients with essential hypertension.

Supplementary material
======================

###### 

Subjects' previous treatment for hypertension

  Previous treatment                    Patients (n)
  ------------------------------------- --------------
  **Single tablet**                     
  Valsartan 80 mg/amlodipine 5 mg       19
  Telmisartan 40 mg/amlodipine 5 mg     12
  Telmisartan 80 mg/amlodipine 5 mg     1
  Candesartan 8 mg/amlodipine 5 mg      3
  **Two tablets**                       
  Candesartan 4 mg/amlodipine 5 mg      2
  Candesartan 4 mg/diltiazem 100 mg     1
  Candesartan 8 mg/amlodipine 5 mg      2
  Candesartan 8 mg/cilnidipine 10 mg    1
  Olmesartan 20 mg/amlodipine 5 mg      2
  Olmesartan 40 mg/amlodipine 5 mg      4
  Olmesartan 40 mg/nifedipine 40 mg     1
  Olmesartan 40 mg/nifedipine 20 mg     1
  Valsartan 20 mg/amlodipine 5 mg       3
  Valsartan 80 mg/amlodipine 5 mg       3
  Valsartan 80 mg/nifedipine 20 mg      1
  Valsartan 80 mg/amlodipine 2.5 mg     1
  Valsartan 80 mg/benidipine 4 mg       1
  Valsartan 160 mg/amlodipine 5 mg      1
  Valsartan 160 mg/nifedipine 40 mg     1
  Telmisartan 40 mg/amlodipine 2.5 mg   1
  Telmisartan 40 mg/amlodipine 5 mg     2
  Telmisartan 40 mg/nifedipine 20 mg    1
  Telmisartan 40 mg/nifedipine 40 mg    1
  Losartan 12.5 mg/amlodipine 2.5 mg    1
  Losartan 100 mg/cilnidipine 10 mg     1
  Losartan 50 mg/diltiazem 100 mg       1
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###### 

Clinical characteristics of subjects

  Variables                                          
  -------------------------------------------------- ------------
  Patients (n)                                       68
  Male                                               34 (50%)
  Age (years)                                        70.8±10.0
  Body mass index (kg/m^2^)                          24.1±3.5
  Systolic blood pressure (mmHg)                     142.1±15.5
  Diastolic blood pressure (mmHg)                    77.7±11.2
  Low-density lipoprotein cholesterol (mg/dL)        109.7±26.3
  Triglycerides (mg/dL)                              130.1±62.6
  High-density lipoprotein cholesterol (mg/dL)       56.8±13.8
  Glycated hemoglobin (%)                            5.9±0.6
  Casual plasma blood glucose (mg/dL)                109.8±23.4
  Serum uric acid (mg/dL)                            5.4±1.4
  Serum potassium (mEq/L)                            4.2±0.4
  Serum creatinine (mg/dL)                           0.81±0.24
  Urinary albumin excretion rate (mg/g creatinine)   51.5±131.3
   Complications                                     
   Dyslipidemia                                      43 (63.2%)
   Coronary artery disease                           13 (19.1%)
   Cerebrovascular disease                           18 (26.5%)
   Diabetes mellitus                                 13 (19.1%)
  Drugs                                              
   Statins                                           34 (50%)
   Ezetimibe                                         2 (2.9%)
   Fibrates                                          0 (0%)
   Dipeptidyl peptidase 4 inhibitors                 4 (5.9%)
   Alpha-glucosidase inhibitors                      4 (5.9%)
   Sulfonylureas                                     0 (0)
   Biguanides                                        0 (0)
   Glinides                                          3 (4.4%)
   Thiazolidinediones                                3 (4.4%)
   Insulin                                           0 (0)

**Note:** Values are expressed as the number (%) or mean ± standard deviation.

###### 

Patients classified by ARB and CCB dose before treatment with the combination tablet containing amlodipine 10 mg and irbesartan 100 mg

                        Low dose of CCB   Regular dose of CCB
  --------------------- ----------------- ---------------------
  Low dose of ARB       1                 6
  Regular dose of ARB   4                 47
  High dose of ARB      1                 9

**Abbreviations:** ARB, angiotensin II receptor antagonist; CCB, calcium channel blocker.

###### 

Changes in blood pressure and cardiovascular risk factors before and 3 months after treatment with the combination tablet containing amlodipine 10 mg and irbesartan 100 mg

  Variables                                          Before treatment   3 months after treatment   *P*-value
  -------------------------------------------------- ------------------ -------------------------- -----------
  Systolic blood pressure (mmHg)                     142.7±16.1         126.1±13.4                 \<0.01
  Diastolic blood pressure (mmHg)                    78.1±11.4          69.4±8.0                   \<0.01
  Heart rate (beats per minute)                      73.5±10.8          74.8±9.5                   0.34
  Low-density lipoprotein cholesterol (mg/dL)        108.0±25.8         102.7±25.3                 0.02
  Triglyceride (mg/dL)                               131.6±64.4         120.3±69.8                 0.09
  High-density lipoprotein cholesterol (mg/dL)       57.5±14.1          60.1±14.6                  \<0.01
  Glycated hemoglobin (%)                            5.9±0.6            5.9±1.3                    0.76
  Casual plasma blood glucose (mg/dL)                112.0±25.8         104.6±20.9                 0.20
  Serum uric acid (mg/dL)                            5.5±1.5            5.1±1.3                    \<0.001
  Serum potassium (mEq/L)                            4.2±0.4            4.3±0.3                    0.76
  Serum creatinine (mg/dL)                           0.82±0.24          0.81±0.24                  0.25
  Urinary albumin excretion rate (mg/g creatinine)   49.8±133.6         50.5±136.4                 0.91

**Note:** Data in the Before treatment and 3 months after treatment columns are presented as mean ± standard deviation.
